期刊
CLINICAL INFECTIOUS DISEASES
卷 59, 期 10, 页码 1455-1461出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciu583
关键词
MRSA bacteremia; vancomycin; daptomycin; rapid diagnostics; persistent bacteremia
资金
- Pfizer
- Cubist
- Forest Pharmaceuticals
Persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia (MRSAB) is associated with poor outcomes and serious complications. The MRSA guidelines define treatment failure and persistent bacteremia as lasting >= 7 days; however, this definition requires reevaluation. Aggressively reducing the bacterial inoculum promptly is critical because factors already in place before clinical presentation are driving resistance to the few antibiotics that are available to treat MRSAB. Alternative approaches to treat MRSAB should be considered within 3-4 days of persistent MRSAB. With rapid molecular diagnostics emerging in clinical microbiology laboratories and biomarkers as a potential for early patient risk stratification, a future shorter threshold may become possible.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据